Prognostic value of bone marrow hematogones in childhood B-lineage acute lymphoblastic leukemia.
- Author:
Yue-Fan WANG
1
;
Yong-Mei JIANG
;
Ju GAO
;
Ping ZHOU
;
Ge ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Bone Marrow; pathology; Child; Child, Preschool; Female; Flow Cytometry; Humans; Infant; Male; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; mortality; pathology; Prognosis; Retrospective Studies
- From: Chinese Journal of Contemporary Pediatrics 2016;18(4):292-296
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the prognostic value of hematogones (HGs) for childhood B-lineage acute lymphoblastic leukemia (B-ALL) during consolidation chemotherapy.
METHODSA retrospective analysis was conducted for 196 children with newly-diagnosed B-ALL. They were divided into high-risk group (n=55), intermediate-risk group (n=69), and low-risk group (n=72) by risk stratification, and into complete remission group (n=165) and relapse group (n=31) by clinical outcome. The European BIOMED-1 standard flow cytometry for minimal residual disease (MRD) was used to determine the number of HGs during consolidation chemotherapy. The Kaplan-Meier survival curve was used to assess event-free survival (EFS).
RESULTSThe high-risk group had a significantly lower number of HGs than the intermediate-risk and low-risk groups (P<0.05). The number of HGs in the complete remission group was significantly higher than in the relapse group (P<0.05). The children with HGs ≤1.0% had a significantly lower EFS than those with HGs <1.0% (P<0.05).
CONCLUSIONSHGs can be used to assess the treatment outcome and prognosis in children with B-ALL, and proliferation of HGs reflects the good effect of chemotherapy in such children.
